Resumo

YUSTE-GUTIERREZ, AM; VILLABONA-RIVAS, I; APARICIO-HERNANDEZ, RM  e  GARCIA-LUQUE, A. Positive assessment of drugs: from November and December of 2022 and January of 2023. Sanid. Mil. [online]. 2023, vol.79, n.1, pp.47-49.  Epub 13-Nov-2023. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-857120230001000010.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from November 2022 to January of 2023, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Cipaglucosidasa alfa (Pombility^®); Deucravacitinib (Sotyktu^®); Etranacogén dezaparvovec (Hemgenix^®); SARS-COV-2 (strain B.1.351) Spike protein (Vidprevtyn beta^®); Tremelimumab (Imjudo^®); Tremelimumab (Tremelimumab Astra Zeneca^®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )